Видео ютуба по тегу Biocon Biologics Issues

Confident That Issues At Malaysian Plant Will Be Behind Once It Is Inspected: Biocon Biologics
Confident That Issues At Malaysian Plant Will Be Behind Once It Is Inspected: Biocon Biologics
Biocon Biologics: Shifting the access paradigm by providing affordable quality insulins worldwide.
Biocon Biologics: Shifting the access paradigm by providing affordable quality insulins worldwide.
Biocon Biologics ISPE FOYA Award
Biocon Biologics ISPE FOYA Award
Managing women’s health issues with conditions like chronic kidney disease during #COVID19
Managing women’s health issues with conditions like chronic kidney disease during #COVID19
Biocon Surges After The US FDA Issues A VAI Status To Its Biologics Unit In Bengaluru | CNBC TV18
Biocon Surges After The US FDA Issues A VAI Status To Its Biologics Unit In Bengaluru | CNBC TV18
Insulin Glargine: Journey to the USFDA Approval
Insulin Glargine: Journey to the USFDA Approval
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Biocon Biologics's Shreehas Tambe Speaks On US FDA's Observation | Bazaar Open Exchange | CNBC-TV18
Biocon Biologics's Shreehas Tambe Speaks On US FDA's Observation | Bazaar Open Exchange | CNBC-TV18
Decoding Biocon Biologics’ Growth Trajectory | Opportunity In Multi-Billion Dollar Biosimilar Space
Decoding Biocon Biologics’ Growth Trajectory | Opportunity In Multi-Billion Dollar Biosimilar Space
Biocon Biologics' Shreehas Tambe Speaks On The Firm's Deal With Japan's Yoshindo | CNBC-TV18
Biocon Biologics' Shreehas Tambe Speaks On The Firm's Deal With Japan's Yoshindo | CNBC-TV18
RAW MATERIAL LOT VARIABILITY CHALLENGES DURING MANUFACTURING OF BIOSIMILARS MAB
RAW MATERIAL LOT VARIABILITY CHALLENGES DURING MANUFACTURING OF BIOSIMILARS MAB
Biocon Biologics' and Serum Institute Life Sciences' Strategic Alliance
Biocon Biologics' and Serum Institute Life Sciences' Strategic Alliance
Highlights Of #Q3FY21
Highlights Of #Q3FY21
Biocon gets 8 observations from USFDA after inspection of Malaysia insulins facility
Biocon gets 8 observations from USFDA after inspection of Malaysia insulins facility
R&D spending: Our pipeline is our 'lifeline,' says Indian biotech firm
R&D spending: Our pipeline is our 'lifeline,' says Indian biotech firm
A $6 Billion Biosimilar Opportunity
A $6 Billion Biosimilar Opportunity
Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business
Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business
Biocon executive among 5 held in 'bribery' case
Biocon executive among 5 held in 'bribery' case